Administration January 8, 2009
Pharmaceutical Company Could Face Company Stock Suit
January 8, 2009 (PLANSPONSOR.com) - The law firm of
Stember Feinstein Doyle & Payne, LLC is investigating
conduct which it believes may have caused losses to the KV
Pharmaceutical Company Profit Sharing Plan and
Trust.
Reported by Rebecca Moore
An announcement from the law firm said it is investigating whether certain fiduciaries of the plan knew or should have known that its statements regarding its financial health and manufacturing processes were inaccurate, which may have caused the price of KV’s shares to be artificially inflated.
Specifically, the firm is investigating whether KV breached its fiduciary obligations under the Employee Retirement Income Security Act (ERISA):
- by continuing to offer KV common stock as an investment option for participant contributions when it was imprudent to do so;
- by failing to take action to sell KV stock or otherwise protect the Plan’s assets; and
- by failing to adequately disclose alleged problems with manufacturing processes and alleged non-compliance with FDA regulations.
Ellen M. Doyle of Stember Feinstein Doyle & Payne has been appointed class counsel to represent numerous classes of ERISA plan participants.
More information is at www.stemberfeinstein.com .
You Might Also Like:
SEC Sued by Red States, Environmental Group, After Finalizing Climate Disclosure
Three separate lawsuits have been filed against the SEC seeking to overturn its final rule.
Lawsuit Targets Fiduciaries of Hess Corp.
A lawsuit against the Hess Corp. alleges Hess plan fiduciaries included target-date mutual funds instead of collective investment trusts in...
Tyson Foods Hit With 401(k) Suit for Overcharging
Employees allege the Tyson Foods plan committee did not monitor and negotiate for reasonable recordkeeper fees.